Webinar Overview
Scientific innovation now presents a unique opportunity to profile early biotherapeutics using synthetic material. This webinar will focus on safety confidence for prenatal patients.
You will learn how prenatal microarray testing can help you build a comprehensive understanding of the binding profile present at 10 to 18 weeks of pregnancy, including primary targets, off-targets, and cross-reactivity. In addition, you will discover how this synthetic prenatal binding profile was developed and how it has been leveraged by leading pharma to enable prenatal safety confidence.
Webinar Presenters
Ellinor Tudge, PhD
Group Leader, DNA Team
Charles River
Curtis Maier, PhD
Head, Immunological Toxicology
GlaxoSmithKline